

Statement of Deficiencies	(X1) Provider/Supplier/CLIA Identification Number 44D0986736	(X3) Date Survey Completed 05/16/2022
Name of Provider or Supplier Pediatric Partners Of Memphis	Street Address, City, State 6063 Mt Moriah Ext Suite 13, Memphis, TN	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D2016	<p>SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c)</p> <p>(a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history.</p> <p>This CONDITION is not met as evidenced by: The laboratory failed to maintain satisfactory participation for two consecutive proficiency testing events for the Hematocrit (HCT) analyte in 2021 event three and 2022 event one, resulting in the first unsuccessful proficiency testing (PT) occurrence for the HCT analyte. (Refer to D2130)</p>
D2130	<p>HEMATOLOGY CFR(s): 493.851(f)</p> <p>Failure to achieve satisfactory performance for the same analyte in two consecutive</p>

events or two out of three consecutive testing events is unsuccessful performance.

This STANDARD is not met as evidenced by:

Based on a desk review of the Centers for Medicare and Medicaid Casper Report 155 (CMS 155) and the laboratory's 2021 and 2022 proficiency testing (PT) evaluation reports, the laboratory failed to maintain satisfactory performance for two consecutive test events for the Hematocrit (HCT) analyte. The findings include: 1. Review of the CMS 155 report revealed the following unsatisfactory HCT scores: a. 2021 event two 60%. b. 2022 event one 60%. 2. Review of the 2021 PT event three evaluation report revealed failed scores for sample numbers HD-14 and HD-15, resulting in an overall score of 60% for the HCT analyte. 3. Review of the 2022 PT event one evaluation report revealed failed scores for sample numbers HD-02 and HD-05, resulting in an overall score of 60% for the HCT analyte and the first unsuccessful PT occurrence.